Figure 2 | Scientific Reports

Figure 2

From: First-in-class topical therapeutic omilancor ameliorates disease severity and inflammation through activation of LANCL2 pathway in psoriasis

Figure 2

Effects of topical omilancor treatment in spleen and local draining lymph nodes (ILN) in IMQ-challenge. At day 7 post-IMQ challenge, spleen and ILN from vehicle and omilancor-treated mice were excised and single cell suspension isolated. Spleen size (A), represented as proportion of total body weight. Using flow cytometry, percentage of TNF+ (B), IL-17+ (C) and IL-21+ (D) CD4+ T cells, and IL-6+ (E) CD45+ cells was assessed in spleen. In draining ILNs, IL-17+ (F) and IL-21+ (G) CD4+ T cells, as well as TNFα-producing macrophages (H) and neutrophils (I) were also quantified using flow cytometry analysis. *P ≤ 0.05.

Back to article page